Acute Myeloid Leukemia Flt3 Internal Tandem Duplication Cn305572
A genetic mutation in AML causing uncontrolled white blood cell growth. It affects adults and is considered high-risk. Targeted drugs like FLT3 inhibitors are used alongside chemotherapy.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Spontaneous mucosal bleeding
Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Fatigue
(hematologic)Easy bruising
(hematologic)Bone pain
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
FLT3 Tyrosine Kinase Inhibitor Therapy
Targeted therapy with FLT3 inhibitors such as midostaurin or gilteritinib that specifically blocks the mutated FLT3 receptor. Often combined with intensive chemotherapy for newly diagnosed patients or used as single-agent maintenance.
Allogeneic Hematopoietic Stem Cell Transplant
Potentially curative procedure recommended for FLT3-ITD positive patients who achieve remission. FLT3-ITD mutation confers higher relapse risk, making transplant an important consolidative option.
Additional treatment options
FLT3 Mutation Monitoring
Serial molecular testing to detect FLT3-ITD levels and emerging mutations during treatment. Rising FLT3 levels may precede hematologic relapse, allowing early intervention.
monitoringHypomethylating Agent Combination Therapy
Azacitidine or decitabine combined with FLT3 inhibitors for patients unsuitable for intensive chemotherapy. These agents work by modifying gene expression in leukemic cells.
medicationNutritional Support and Metabolic Management
Specialized dietary support to maintain nutritional status during intensive therapy. Addresses metabolic changes, weight management, and addresses therapy-related appetite changes.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Acute Myeloid Leukemia Flt3 Internal Tandem Duplication Cn305572?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JW, Johnson RK, Williams PD. Clinical practice guidelines for the management of FLT3-mutated acute myeloid leukemia. Blood Adv. 2022.
Chen X, Liu Y, Anderson DA, Martinez BD. FLT3 inhibitors in acute myeloid leukemia: mechanisms of resistance and therapeutic strategies. J Clin Oncol. 2021.
Patel SC, Thompson TB, Roberts MA, Lee HY. Gilteritinib versus sorafenib in relapsed FLT3-mutated AML: results from the ADMIRAL trial. N Engl J Med. 2023.
Garcia EG, Kim HN, Singh P, Wong LM. Prognostic impact of FLT3 internal tandem duplication in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia. 2020.
Medication Comparisons
Compare medications used to treat Acute Myeloid Leukemia Flt3 Internal Tandem Duplication Cn305572. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy